T2 Biosystems Inc.'s MR-based benchtop diagnostic device detects a deadly bloodstream infection in two hours, according to study results released today, meaning it could cut the mortality rate from Candida fungal blood infections by 73 percent.
T2 Biosystems Inc. says its new blood test for the cause of a deadly blood pathogen could help make huge reductions in the mortality rate in people infected with the fungus Candida.
North Carolina’s nanotechnology sector may not be one of the country's largest, but the state's strong life sciences industry could provide it with significant growth potential.
North Carolina’s nanotechnology presence doesn’t immediately come to mind when thinking of the country’s biggest nanotech hubs, a skeptic of the industry recently told MedCity News.
In a way, he’s right, at least right now. Nanotechnology has found a comfortable home in manufacturing and industrial applications that were developed primarily at tech hubs in other parts of the country.
Liquidia Technologies, a North Carolina-based nanotech company, lands a $10 million equity investment from the Bill & Melinda Gates Foundation to support vaccine development.
Nanotechnology company Liquidia Technologies has received a $10 million equity investment from the Bill & Melinda Gates Foundation to support vaccine development and commercialization.
The financing follows the announcement last month of a collaborative agreement with the PATH Malaria Vaccine Initiative, which is working with Liquidia to develop next-generation malaria vaccines using the Morrisville, N.C.-based company’s nanotechnology methods.
We're on the cusp of a significant new era in medical device design, Nano Surfaces CEO Joe Gatto tells MassDevice, in which their very surfaces will build themselves and be able to operate at the molecular level.
Coming generations of implanted medical devices will interact with the human body at the molecular level, using sophisticated nano-coatings to not only thwart microbial growth but to perform biological operations.
That's the prediction of Nano Surfaces founder, president and CEO Joe Gatto. The Boston-based firm is developing technology it's licensed from Cornell University to create self-assembling, anti-microbial coatings on a nanotech scale — and Gatto says that's just the beginning. To prove it, he's hitting to road to raise a Series A round from institutional investors.
To mimic cells' physiologic features, scientists work at the nanoscale – creating structures at the range of 1 billionth of a meter, 100 times smaller than a red blood cell.
By Tal Dvir
As tissue engineers, we seek to develop functioning substitutes for damaged tissues and organs. Generally, this means seeding cells onto 3-dimensional porous scaffolds made of biomaterials, which provide mechanical support and instructive cues for the developing engineered tissue. Now it’s time to go to the next level, and make complex tissues that can really do things (PDF) — contract, release growth factors, conduct electrical signals and more. Things our own cells and tissues do.
Semprus Biosciences Corp. closes an $18 million Series B funding round, which CEO David Lucchino says it will use to build out its management team and fund manfuacturing ramp-up for its nanotech catheter coating.
Semprus BioSciences Corp. reeled in $18 million in Series B financing for its nanotech medical device coating.
Semprus CEO David Lucchino told MassDevice that the company will use the proceeds to build a team of "been there, done that" medical device executives and to scale up its manufacturing operations.
"Investor expectations with this round of funding are that we would gain regulatory and clinicial clarity, along with having an initial product in hand to start initial sales. We're looking at the next 24 months as being that window," Lucchino told us.
Audax Medical Inc. inks an exclusive license agreement with Brown University for Arxis, a biomaterial that the two are developing for regenerative medicine applications.
Audax Medical Inc. entered into partnership deal with Brown University for a nanotechnology-based biomaterial for regenerative medicine.
The licensing agreement gives the Littleton, Mass.-based company exclusive rights to Arxis, which is based on an organic osteobiologic developed at the university's School of Engineering and Dept. of Orthopedics.